Biopsies and blood tests for advanced melanoma
Part of Cancer, Skin clinical trials.
This study looks at serial (repeated) tumour biopsies and blood samples in people with advanced melanoma. The goal is to understand biomarkers and disease changes over time, which may help improve future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 16 or older
- You can give written informed consent (or your legal guardian can, if applicable)
- You have melanoma that is stage III or stage IV (locally advanced or metastatic)
- There is a tumour spot that doctors can safely biopsy (they may use imaging or surgery)
- If you join the biopsy/blood part, your recent blood count and clotting tests must be acceptable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This trial is looking at a protein called CD160 on immune cells (NK cells) in melanoma patients. The goal is to understand if this protein can be a target for new treatments. By studying your blood and tumor samples, researchers hope to find better ways to treat advanced melanoma.
This study looks at your melanoma's gene activity and a blood test for tumor DNA to help predict the risk of the cancer coming back. You will need to provide blood and tissue samples, and the goal is to find better ways to personalize treatment for people with thicker, high-risk melanomas.
This trial studies how your immune system “profiles” change while you’re treated with immunotherapy for melanoma. Results may help doctors better understand who benefits from treatment and when.
This study collects and stores leftover melanoma tissue (and sometimes blood) for future research and testing. If the trial uses your stored samples to help match treatments, it could support better care planning over time.
This study tests if giving you targeted therapy pills (encorafenib and binimetinib) only when a blood test shows your cancer is active — instead of continuously — can help keep the melanoma under control with fewer side effects. It is designed for people with advanced melanoma that has a BRAF mutation.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.